J. Goldman & CO LP Mirati Therapeutics, Inc. Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $344,018 - $495,895	-2,606 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $344,330 - $462,434	2,606 New	2,606 $461,000
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $314,598 - $572,911	-4,446 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $1.42 Million - $2 Million	-18,209 Reduced 80.38%	4,446 $346,000
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $1.35 Million - $2.37 Million	22,655 New	22,655 $2.33 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.